Clinical trial
CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer
NCT00434031 · National Cancer Institute, Naples, Other · Withdrawn
Key facts
| NCT number | NCT00434031 |
|---|---|
| Title | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer |
| Official title | Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer |
| Acronym | CETRA |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, cyclophosphamide, trastuzumab, liposomal doxorubicin |
| Enrollment | 0 |
| Start date | Sep 1, 2007 |
| First posted | Feb 12, 2007 |
| Last update posted | Jul 30, 2012 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: